Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr75.00 SEK
Change Today 0.00 / 0.00%
Volume 43.7K
MVIRB On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
OTC US
Frankfurt
As of 7:26 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Open
kr75.00
Previous Close
kr75.00
Day High
kr76.00
Day Low
kr74.25
52 Week High
09/8/14 - kr131.13
52 Week Low
06/30/15 - kr69.00
Market Cap
2.0B
Average Volume 10 Days
94.3K
EPS TTM
kr20.05
Shares Outstanding
26.4M
EX-Date
--
P/E TM
3.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based pharmaceutical company, develops and sells pharmaceuticals for the treatment of infectious diseases, osteoarthritis, neuropathic pain, and oncology in the Nordic region. It focuses on the research and development of pharmaceuticals primarily in the hepatitis C area; osteoarthritis; neuropathic pain; respiratory syncytial virus; and HIV/AIDS. The company sells 16 prescription pharmaceuticals under various brands, including Mollipect, Citodon, Digoxin BioPhausia, Egazil, Laxabon, Lithionit, Morfin Special, Nitroglycerin BioPhausia, Paraflex, Probecid, Solvezink, Suscard, Teovent, and Theo-Dur. It has a collaboration agreement with Cancer Research Technology to develop cancer drugs. Medivir AB is headquartered in Stockholm, Sweden.

138 Employees
Last Reported Date: 08/20/15

medivir ab-b shs (MVIRB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr1.9M
Compensation as of Fiscal Year 2014.

medivir ab-b shs (MVIRB) Key Developments

Medivir AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Medivir AB reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's net turnover was SEK 245.8 million against SEK 564.0 million a year ago. Operating profit before depreciation and amortisation (EBITDA) was SEK 104.9 million against SEK 424.4 million a year ago. Operating profit (EBIT) was SEK 96.1 million against SEK 416.2 million a year ago. Profit before tax was SEK 85.4 million against SEK 418.4 million a year ago. Profit after tax was SEK 64.1 million or SEK 2.19 diluted per share against SEK 327.8 million or SEK 10.28 diluted per share a year ago. Cash flow from operating activities was SEK 64.3 million against SEK 88.7 million a year ago. Return on equity was 5.8% against 32.2% a year ago. For the six months, the company's net turnover was SEK 461.7 million against SEK 772.2 million a year ago. Operating profit before depreciation and amortisation (EBITDA) was SEK 189.6 million against SEK 521.2 million a year ago. Operating profit (EBIT) was SEK 172.2 million against SEK 504.9 million a year ago. Profit before tax was SEK 168.2 million against SEK 508.7 million a year ago. Profit after tax was SEK 130.7 million or SEK 4.46 diluted per share against SEK 611.7 million or SEK 19.18 diluted per share a year ago. Cash flow from operating activities was SEK 269.6 million against SEK 31.0 million a year ago. Return on equity was 9.7% against 43.9 % a year ago.

Medivir Announces Start of Phase I Clinical Trial of the Nucleotide Polymerase Inhibitor Al-704 for Treatment of Hepatitis C

Medivir AB announced the start of a phase I clinical trial with AL-704, also known as JNJ-54257099, by Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies. AL-704 is a nucleotide based NS5B polymerase inhibitor intended for the treatment of chronic hepatitis C virus (HCV) infection in combination with other direct acting antiviral agents. Medivir entered a Research & Development agreement in the field of HCV polymerase with Janssen Products LP in May 2008. AL-704 is the second candidate drug under this agreement that enters into clinical development, and thus no additional milestone payment is due for this specific step of development. This phase I study is a randomized, double-blind, placebo-controlled, 3-part study of orally administered AL-704 to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses (Part 1) and food-effect (Part 2) in healthy volunteers, and multiple doses (7 days) in subjects with chronic hepatitis C infection of genotype 1 and 3 (Part 3).

Medivir AB Reports Sales Results for the Second Quarter of 2015

Medivir AB reported sales results for the second quarter of 2015. For the second quarter of 2015, the company's total global net sales of USD 264 million against USD 832 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr75.00 SEK 0.00

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies
 

Industry Analysis

MVIRB

Industry Average

Valuation MVIRB Industry Range
Price/Earnings 3.4x
Price/Sales 1.5x
Price/Book 1.3x
Price/Cash Flow 3.0x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit www.medivir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.